Phenom Recognized as a Strategic Leader in Fosway’s 2022 9-Grid™ for Talent Acquisition for Second Consecutive Year
4.5.2022 16:36:00 EEST | Business Wire | Press release
Phenom, the leading AI-powered talent experience platform, has been named a Strategic Leader in the 2022 Fosway 9-Grid™ for Talent Acquisition for the second year in a row. Fosway identifies Strategic Leaders as companies that provide a rich suite of capability across a broad scope of features and have the sophistication to consistently meet the needs of complex enterprise-scale customers. According to Fosway, Phenom has proven its ability to deliver higher levels of innovation, customer impact and advocacy compared to alternatives in the market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220503006092/en/
Phenom positioned as Strategic Leader in Fosway 9-Grid (Graphic: Business Wire)
With the highest job vacancy rate Europe has seen in 14 years, the talent shortage has developed into a crisis that extends far beyond human resources. To better connect with candidates and quickly fill open roles, CHROs and CEOs from today’s leading enterprises are choosing systems of intelligence to automate tasks and provide personalised experiences that job seekers expect in today’s competitive talent market.
Phenom’s position as a Strategic Leader reinforces that its Talent Experience Management (TXM) platform is enabling enterprises with the AI and automation necessary to quickly identify and hire best-fit talent, and an intelligent talent marketplace to develop and retain their best employees.
“Organisations are facing acute recruitment challenges that require innovative approaches to talent acquisition," said David Wilson, CEO, Fosway Group. "Phenom has consolidated its position as a Strategic Leader on the 2022 Fosway 9-Grid™ for Talent Acquisition through its focus on innovation and harnessing talent intelligence to deliver better recruitment outcomes for customers."
In 2021, 50,000 recruiters, talent marketers and hiring managers used Phenom to hire over 2 million people and engage over 5 million employees. Built on a vast network of data, contextual industry models and deep learning, the Phenom TXM platform is empowering organisations to:
- Engage & hire best-fit candidates faster: Connecting job seekers with relevant job recommendations and content based on skills, experience and location with a personalised Career Site, conversational Chatbot and CMS.
- Improve recruiter productivity: Identifying best-fit talent for open roles and automating tedious administrative tasks with a talent CRM, Campaigns, AI Scheduling, Video Assessments and AI Insights.
- Develop and retain employees: Fostering employee engagement, growth, and retention with an Internal Talent Marketplace, Career Pathing, Internal Mobility, Gigs, Diversity, Equity & Inclusion and Employee Resource Groups.
- Enable hiring managers: Streamlining collaboration with managers and elevating meaningful insights through talent analytics.
AXA, a global insurance company and Phenom customer, continues to see new value in the Phenom platform every day.
“With Phenom, it’s easier than ever for employees and candidates to explore open jobs across our organisation. Since the platform is constantly capturing and analyzing data, it’s delivering personalized experiences to help everyone find the right fit. When we’re able to connect people with opportunities where they can shape the way they work and realize their potential, that’s the greatest achievement of all,” said Amanda Vaughan, Global Head of Talent & Learning at AXA.
“As enterprises rely on talent experience to meet hiring demands in EMEA, maintaining our position as a Strategic Leader in Fosway’s Talent Acquisition grid signifies how we’re planting our roots in the HR technology market,” said Jeff Carey, senior vice president of international business at Phenom. “Our customers chose Phenom as the AI-powered solution to not only help them find candidates faster and retain talent today — they’re also investing in our constant innovation to ensure they’re future-proofed for the inevitable demands that will arise tomorrow.”
Companies across EMEA are successfully adopting Phenom’s talent experience platform to help candidates find the right job faster, recruiters discover best-fit talent, employees learn and evolve and managers build their teams. To support the growing need for Talent Experience Management, Phenom acquired three Europe-based companies and now has employees based in countries including Germany, France, Ireland, the Netherlands, Switzerland, Italy, Spain and the United Kingdom.
To learn more about Phenom’s Strategic Leader position, please visit their blog.
To see Fosway’s full analysis, check out their 2022 9-grid™.
About Phenom
Phenom is a global HR technology company with a purpose to help a billion people find the right job. With an expertise in building AI-powered, scalable solutions, Phenom Talent Experience Management (TXM) personalises and automates the talent journey for candidates, recruiters, employees and managers with its Career Site, Chatbot, CRM, CMS, SMS and Email Campaigns, University Recruiting, Internal Mobility, Career Pathing, Diversity & Inclusion, Talent Marketplace, Gigs, Referrals, Hiring Manager and Analytics. As a result, employers improve their talent acquisition and talent management efforts by helping candidates find the right job, employees grow and evolve, recruiters discover top talent, and managers build teams faster. Phenom was a winner in the Business Intelligence Group’s 2021 Artificial Intelligence Excellence Awards program for its sophisticated machine learning capabilities and was ranked among the fastest-growing private companies in the 2021 Inc. 5000.
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, Twitter, Facebook, YouTube and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503006092/en/
Contact information
Media:
Jennifer Lyons
Director, Global Communications
267-379-5066
jennifer.lyons@phenompeople.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom